| BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA, Elena MOROZOVA, Aleksandra GOLOS, Philipp ERNST, Ulla OLSSON-STROMBERG, Daniela ŽÁČKOVÁ, Franck E NICOLINI, Han BAO, Fausto CASTAGNETTI, Elzbieta PATKOWSKA, Jiří MAYER, Klaus HIRSCHBUEHL, Helena PODGORNIK, Edyta PACZKOWSKA, Anne PARRY, Thomas ERNST, Astghik VOSKANYAN, Elzbieta SZCZEPANEK, Susanne SAUSSELE, Georg-Nikolaus FRANKE, Alexander KIANI, Edgar FABER, Stefan KRAUSE, Luis Felipe CASADO, Krzysztof LEWANDOWSKI, Matthias EDER, Peter ANHUT, Justyna GIL, Thomas SUEDHOFF, Holger HEBART, Sonja HEIBL, Markus PFIRRMANN, Andreas HOCHHAUS and Michael LAUSEKER. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. London: Nature Publishing Group, 2024, 9 pp. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-024-02204-y. |
Other formats:
BibTeX
LaTeX
RIS
@article{2407802,
author = {Brioli, Annamaria and Lomaia, Elza and Fabisch, Christian and Sacha, Tomasz and Klamova, Hana and Morozova, Elena and Golos, Aleksandra and Ernst, Philipp and OlssonandStromberg, Ulla and Žáčková, Daniela and Nicolini, Franck E and Bao, Han and Castagnetti, Fausto and Patkowska, Elzbieta and Mayer, Jiří and Hirschbuehl, Klaus and Podgornik, Helena and Paczkowska, Edyta and Parry, Anne and Ernst, Thomas and Voskanyan, Astghik and Szczepanek, Elzbieta and Saussele, Susanne and Franke, GeorgandNikolaus and Kiani, Alexander and Faber, Edgar and Krause, Stefan and Casado, Luis Felipe and Lewandowski, Krzysztof and Eder, Matthias and Anhut, Peter and Gil, Justyna and Suedhoff, Thomas and Hebart, Holger and Heibl, Sonja and Pfirrmann, Markus and Hochhaus, Andreas and Lauseker, Michael},
article_location = {London},
doi = {http://dx.doi.org/10.1038/s41375-024-02204-y},
keywords = {chronic myeloid leukemia; tyrosine kinase inhibitor era},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry},
url = {https://www.nature.com/articles/s41375-024-02204-y},
year = {2024}
}
TY - JOUR
ID - 2407802
AU - Brioli, Annamaria - Lomaia, Elza - Fabisch, Christian - Sacha, Tomasz - Klamova, Hana - Morozova, Elena - Golos, Aleksandra - Ernst, Philipp - Olsson-Stromberg, Ulla - Žáčková, Daniela - Nicolini, Franck E - Bao, Han - Castagnetti, Fausto - Patkowska, Elzbieta - Mayer, Jiří - Hirschbuehl, Klaus - Podgornik, Helena - Paczkowska, Edyta - Parry, Anne - Ernst, Thomas - Voskanyan, Astghik - Szczepanek, Elzbieta - Saussele, Susanne - Franke, Georg-Nikolaus - Kiani, Alexander - Faber, Edgar - Krause, Stefan - Casado, Luis Felipe - Lewandowski, Krzysztof - Eder, Matthias - Anhut, Peter - Gil, Justyna - Suedhoff, Thomas - Hebart, Holger - Heibl, Sonja - Pfirrmann, Markus - Hochhaus, Andreas - Lauseker, Michael
PY - 2024
TI - Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
JF - Leukemia
PB - Nature Publishing Group
SN - 08876924
KW - chronic myeloid leukemia
KW - tyrosine kinase inhibitor era
UR - https://www.nature.com/articles/s41375-024-02204-y
N2 - Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.
ER -
BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA, Elena MOROZOVA, Aleksandra GOLOS, Philipp ERNST, Ulla OLSSON-STROMBERG, Daniela ŽÁČKOVÁ, Franck E NICOLINI, Han BAO, Fausto CASTAGNETTI, Elzbieta PATKOWSKA, Jiří MAYER, Klaus HIRSCHBUEHL, Helena PODGORNIK, Edyta PACZKOWSKA, Anne PARRY, Thomas ERNST, Astghik VOSKANYAN, Elzbieta SZCZEPANEK, Susanne SAUSSELE, Georg-Nikolaus FRANKE, Alexander KIANI, Edgar FABER, Stefan KRAUSE, Luis Felipe CASADO, Krzysztof LEWANDOWSKI, Matthias EDER, Peter ANHUT, Justyna GIL, Thomas SUEDHOFF, Holger HEBART, Sonja HEIBL, Markus PFIRRMANN, Andreas HOCHHAUS and Michael LAUSEKER. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. \textit{Leukemia}. London: Nature Publishing Group, 2024, 9 pp. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-024-02204-y.
|
